Prospective observational study on prevention methods and causes of vasculitis and vascular pain caused by vinorelbine

Prospective observational study on prevention methods and causes of vasculitis and vascular pain caused by vinorelbine - Prospective observational study on prevention methods and causes of vasculitis and vascular pain caused by vinorelbine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052208

Enrollment

Registered

2023-09-18

Start date

2023-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: :Prospective observation group: 1) Patients undergoing postoperative chemotherapy using a combination of cisplatin and vinorelbine after lung cancer surgery 2) Patients who can consent to conduct this study 3) Patients who can express their own will to consent to this study Retrospective observation group: 1) Patients who received postoperative chemotherapy using a combination of cisplatin and vinorelbine after lung cancer surgery person

Exclusion criteria

Exclusion criteria: Exclusion criteria: Prospective observation group: 1) Used for treatments other than cisplatin + vinorelbine combination therapy for lung cancer Patients on regimens containing vinorelbine 2) Patients with heart failure 3) Patients with poor renal function Retrospective observation group: 1) Used for treatments other than cisplatin + vinorelbine combination therapy for lung cancer Patients on regimens containing vinorelbine 2) Patients with a history of heart failure 3) Patients with poor renal function 4) This treatment is performed on the 1st day and the 8th day, but patients who complete the treatment without performing the treatment on the 8th day

Design outcomes

Primary

Measure	Time frame
Frequency, severity, and range of vascular pain and vasculitis after administration of vinorelbine	—

Secondary

Measure	Time frame
Electrolyte abnormalities, appearance of edema, incidence of heart failure, and BNP	—

Countries

Japan

Contacts

Public ContactShunichi ISHII

Showa University School of Pharmacy Department of Hospital Pharmaceutics

shun.pharm@cmed.showa-u.ac.jp03-3784-8000

Outcome results